| Literature DB >> 36059979 |
Muhammad Noman1, Neelum Gul Qazi1, Najeeb Ur Rehman2, Arif-Ullah Khan1.
Abstract
Gastric ulcer is one of the most common chronic gastrointestinal diseases characterized by a significant defect in the mucosal barrier. The current study has been conducted to evaluate the brucine anti-ulcer effect. Brucine has binding energy values ranging from -2.99 to -8.11 kcal/mol against chosen targets, according to in silico research. Brucine exhibits an inhibitory effect against Helicobacter pylori. In vivo findings revealed that brucine (3 mg/kg) showed effective results in healing ethanol-induced ulcer lesions of the gastric region in rats. Brucine showed an inhibitory effect against H+/K+-ATPase. Levels of glutathione, glutathione-s-transferase, and catalase were enhanced in the gastric rat tissue with the use of brucine, while a significant decrease in lipid peroxide levels was seen. Histopathological evaluation showed improvement in cellular architecture and a decrease in inflammatory indicators like cyclooxygenase, tumor necrosis factor, and nuclear factor kappa B expression, validated through immunohistochemistry, enzyme-linked immunosorbent assay, and Western blot techniques. In the reverse transcription-polymerase chain reaction, brucine decreased H+/K+-ATPase mRNA levels. This study reveals that brucine possesses stable binding affinities against selected targets. Brucine exhibits an anti-ulcer effect, mediated via anti-H. pylori, H+/K+-ATPase inhibition, and antioxidant and anti-inflammatory pathways.Entities:
Keywords: H+/K+-ATPase; anti-H. pylori; anti-inflammatory; anti-ulcer; antioxidant; brucine
Year: 2022 PMID: 36059979 PMCID: PMC9429807 DOI: 10.3389/fphar.2022.886433
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1(A, B) represent 2D and 3D structures of brucine.
Binding energy (kcal/mol) and post-dock analysis of the best conformational pose of brucine with H+/K+-ATPase, histaminergic (H2) receptor, cyclooxygenase (COX-1), tumor necrosis factor (TNF-α), nuclear factor kappa B (NFκB), prostaglandin (PGE2), cyclooxygenase (COX-2), and muscarinic (M1) receptor.
| Brucine | Standard drug | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Target protein | PDB ID | E-value (Kcal/mol) | H-bond | H-bonding residue | Binding residue forming other hydrophobic interactions | Drug name | E-value (Kcal/mol) | H-bond | H-bonding residue | Binding residue forming other hydrophobic interactions |
| H+/K+-ATPase | 5YLU | −8.7 | — | — | ASN138 | Omeprazole | −8.2 | 2 | CYS813 | ILE816 |
| ARG328 | LEU141 | |||||||||
| VAL331 | LEU796 | |||||||||
| GLN127 | TYR799 | |||||||||
| THR135 | ALA335 | |||||||||
| ASP137 | ALA339 | |||||||||
| H2 | H2P2501 | −8.1 | 2 | ASN292TYR202 | THR53 | Ranitidine | −8.5 | — | — | VAL113 |
| ILE112 | TRP387 | |||||||||
| ILE57 | TYR381 | |||||||||
| TYR288 | ALA196 | |||||||||
| COX-1 | 6Y3C | −7.6 | 2 | HIS90 | GLY354 | Aspirin | −6.9 | 1 | LYS231 | ARG116 |
| HIS95 | ASN515 | ASN54 | ||||||||
| GLN192 | ASN292 | |||||||||
| SER353 | TYR288 | |||||||||
| SER516 | TYR202 | |||||||||
| TNF-α | 1BKC | −8.11 | 1 | PRO437 | HIS415 | Aspirin | −6.2 | 3 | SER121 | THR118 |
| ILE438 | GLN372 | ASN122 | ||||||||
| ALA439 | LYS532 | |||||||||
| HIS405 | ||||||||||
| LEU348 | ||||||||||
| NFκB | 4Q3J | −8.58 | 2 | ASN240 | TYR227 | Curcumin | 8.42 | 4 | GLN372 | TYR374 |
| ARG23 | GLU207 | LYS532 | PRO543 | |||||||
| GLU179 | SER121 | ALA544 | ||||||||
| GLY180 | ILE124 | SER126 | ||||||||
| GLU184 | HIS122 | |||||||||
| PGE2 | 6AK3 | −6.92 | - | - | TRP344 | Dinoprostone | 8.24 | 5 | ARG333 | PHE140 |
| THR206 | ||||||||||
| TYR114 | ||||||||||
| SER336 | ||||||||||
| THR107 | ||||||||||
| COX-2 | 5IKQ | −2.99 | 1 | SER127 | ASP126 | Meclofenamate | 7.13 | 4 | GLU184 | PRO147 |
| ALA543 | CYS149 | ILE148 | ||||||||
| PRO542 | ARG237 | LEU236 | ||||||||
| SER541 | ASN240 | |||||||||
| M1 | 5CXV | −8.74 | 1 | ILE180 | TYR85 | Phenoxy benzamine | −5.20 | 4 | GLY349 | THR347 |
| TYR82 | HIS405 | LEU348 | ||||||||
| TRP400 | HIS409 | GLU406 | ||||||||
Standard inhibitors or activators of pathways are omeprazole, phenoxy benzamine, ranitidine, aspirin, meclofenamate, dinoprostone, and curcumin. Amino acids are arginine (ARG), isoleucine (ILE), asparagine (ASN), tyrosine (TYR), histidine (HIS), threonine (THR), glutamic acid (GLU), proline (PRO), phenylalanine (PHE), valine (VAL), glycine (GLY), tryptophan (TRP), leucine (LEU), cystine (CYS), aspartic acid (ASP), alanine (ALA), and serine (SER).
Antibacterial effect of brucine against three clinical strains of H. pylori using the disk diffusion method.
| Sample | Zone of inhibition (mm) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0.5 µg/disk | 1 µg/disk | 2 µg/disk | 4 µg/disk | 8 µg/disk | 16 µg/disk | 32 µg/disk | MIC50 (µg/ml) | |
|
| ||||||||
| Brucine | 1 ± 0 | 1.33 ± 0.33 | 2 ± 0.57 | 4 ± act0.57 | 8 ± 0.57 | 10.66 ± 0.33 | 14 ± 0.57 | 16 |
| Metronidazole | 3.66 ± 0.33 | 4.66 ± 0.33 | 5.33 ± 0.66 | 7 ± 0.57 | 10.33 ± 1.20 | 14.66 ± 0.88 | 22 ± 1.15 | 4 |
|
| ||||||||
| Brucine | 1.33 ± 0.33 | 1.66 ± 0.66 | 2 ± 0.57 | 4.66 ± 0.33 | 7.33 ± 0.33 | 10 ± 0.57 | 13 ± 0.57 | 18 |
| Metronidazole | 4 ± 0.57 | 5 ± 0.57 | 5 ± 0.57 | 7.33 ± 0.88 | 10.3 ± 1.20 | 15 ± 1.00 | 20.6 ± 1.33 | 6 |
|
| ||||||||
| Brucine | 1.66 ± 0.33 | 2 ± 0.57 | 2.33 ± 0.33 | 4.33 ± 0.88 | 8.66 ± 0.33 | 11.66 ± 0.88 | 14 ± 0.57 | 16 |
| Metronidazole | 4 ± 0.57 | 4.66 ± 0.33 | 5.66 ± 0.88 | 8 ± 1.15 | 11.33 ± 0.66 | 15.6 ± 0.33 | 22.6 ± 0.66 | 4 |
Protective effect of brucine and omeprazole against ethanol-induced gastric ulcer in rats.
| Treatment (mg/kg) | Ulcer index (UI) | % Inhibition |
|---|---|---|
| Saline (10 ml/kg) | 0 ± 0 | _ |
| Ethanol (1 mL/100 g) | 10 ± 0.00### | 0 |
| Brucine (1 mg/kg) + ethanol (1 mL/100 g) | 2 ± 0.93∗∗∗ | 80 |
| Brucine (3 mg/kg) + ethanol (1 mL/100 g) | 2 ± 0.31∗∗∗ | 80 |
| Omeprazole (20 mg/kg) + ethanol (1 mL/100 g) | 1 ± 0.13∗∗∗ | 90 |
### p < 0.001 compared to the control saline group; ∗∗∗ p < 0.001 vs. the ethanol group. One-way analysis of variance followed by post hoc Tukey’s test, ± SEM (n = 5).
FIGURE 2Gross appearance of gastric mucosa in rats: (A) pretreated with saline, (10 mL/kg). (B) Severe injuries are seen, extensive visible hemorrhagic necrosis of gastric mucosa was produced by absolute ethanol (1 mL/100g), (C, D) pretreated with brucine at doses of 1 and 3 mg/Kg, and (E) pretreated with omeprazole 20 mg/Kg.
FIGURE 3Inhibitory effect of brucine and omeprazole against H+/K+-ATPase in ethanol-induced ulcer rat gastric tissues. Values expressed as mean ± SEM (n = 5). One-way ANOVA with post hoc Tukey’s test was applied. ###p < 0.001 vs. saline group; ∗∗∗p < 0.001 vs. ethanol group.
FIGURE 4Effect of brucine and omeprazole against glutathione sulfotransferases (GST), reduced glutathione (GSH), catalase, and lipid peroxidase (LPO) in ethanol-induced ulcer rat gastric tissues. Data presented as mean ± SEM (n = 5). One-way ANOVA with post hoc Tukey’s test. ### p < 0.001 vs. saline group; p < 0.001 vs. ethanol group.
FIGURE 5Histopathological slides represent effect of brucine and omeprazole in ethanol- induced ulcer rats gastric tissues. Saline group showing normal histological features. Ethanol ulcer group showing marked histopathological deformities by loss of stomach architecture, vacuolization and cloudy swelling. Brucine and omeprazole treatment groups showing near normal architecture with mild to moderate deformities.
FIGURE 6Slides represent the effect of brucine and omeprazole against the expressions of cyclooxygenase (COX-2), nuclear factor kappa B (p-NFκB), and tumor necrosis factor alpha (TNF-α) in ethanol-induced ulcer rat gastric tissues, using the immunohistochemical technique.
FIGURE 7Effects of brucine and omeprazole against cyclooxygenase (COX-2), nuclear factor kappa B (p-NFκB), and tumor necrosis factor alpha (TNF-α) in ethanol-induced ulcer rat gastric tissues, using the immunohistochemical technique. Values expressed as mean ± SEM (n = 5). Data were analyzed by one-way ANOVA, followed by post hoc Tukey’s test. ### p < 0.001 vs. saline group. p < 0.001 vs. ethanol group.
FIGURE 8Effects of brucine and omeprazole against nuclear factor kappa B (p-NFκB), prostaglandin (PGE2), and tumor necrosis factor (TNF-α) levels in ethanol-induced ulcer rat gastric tissues, using the enzyme-linked immunosorbent assay technique. Values expressed as mean ± SEM (n = 5). One-way ANOVA with post hoc Tukey’s test. ### p < 0.001 vs. saline group. *p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. ethanol group.
FIGURE 9Bands (A) and graphical (B) representation of effects of brucine and omeprazole against phosphorylated nuclear factor kappa B (p-NFκB) and tumor necrosis factor (TNF-α) expressions in ethanol-induced ulcer rat gastric tissues, using the Western blot technique. Values expressed as mean ± SEM (n = 5). One-way ANOVA with post hoc Tukey’s test. ### p < 0.001 vs. saline group. ***p < 0.001 vs. ethanol group.
FIGURE 10Effect of brucine and omeprazole against H+/K+-ATPase mRNA expression in ethanol-induced ulcer-treated rat gastric tissues, using the reverse transcription–polymerase chain reaction (RT-PCR) technique. One-way ANOVA followed by post hoc Tukey’s test. Values expressed as mean ± SEM (n = 5). ### p < 0.001 vs. saline group; ∗∗∗p < 0.001 vs. ethanol group.